Combined inhibition of HDAC3 and EZH2 induced restoration of miR-29 and suppressed lymphoma cell growth, suggesting the MYC–EZH2–miRNA axis could be a promising target for epigenetic therapy in B cell lymphoma. The gene discussed is HDAC3; the disease is B-cell non-Hodgkin lymphoma.